Merck & Company, Inc.

As of June 30, 2026, Merck & Co., Inc. Shs Unsponsored Brazilian Depository Receipt Repr 0.125 Sh carries a market capitalization of 1.65T, placing it among publicly traded companies globally. Its enterprise value stands at 1.89T, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Merck & Co., Inc. Shs Unsponsored Brazilian Depository Receipt Repr 0.125 Sh's next confirmed earnings release is scheduled for October 29, 2026.

As of June 30, 2026, Merck & Co., Inc. Shs Unsponsored Brazilian Depository Receipt Repr 0.125 Sh has 19.69B shares outstanding.

As of June 30, 2026, Merck & Co., Inc. Shs Unsponsored Brazilian Depository Receipt Repr 0.125 Sh trades at a trailing price-to-earnings ratio of 100.77. The price-to-sales ratio is 4.80, and the price-to-book ratio stands at 7.60.

As of June 30, 2026, Merck & Co., Inc. Shs Unsponsored Brazilian Depository Receipt Repr 0.125 Sh trades at an EV/EBITDA multiple of 27.93 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 5.49 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 57.33 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Merck & Co., Inc. Shs Unsponsored Brazilian Depository Receipt Repr 0.125 Sh trades at an EV/FCF ratio of 17.50, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 1.89T versus a market cap of 1.65T, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Merck & Co., Inc. Shs Unsponsored Brazilian Depository Receipt Repr 0.125 Sh maintains a current ratio of 1.32, meaning it holds 1.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 128.40, indicating elevated leverage, while an interest coverage ratio of 7.52 demonstrates adequate ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Merck & Co., Inc. Shs Unsponsored Brazilian Depository Receipt Repr 0.125 Sh posted a return on equity (ROE) of 6.98, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 3.61 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 2.57, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 4.55, useful for judging operating efficiency across full business cycles. The company generates approximately 4.59M in revenue per employee across its workforce of 75,000.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.81 indicates how many times Merck & Co., Inc. Shs Unsponsored Brazilian Depository Receipt Repr 0.125 Sh sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Merck & Co., Inc. Shs Unsponsored Brazilian Depository Receipt Repr 0.125 Sh recorded 14.36B in income tax expense. That works out to an effective tax rate of 46.72, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 30.75B, leaving 16.40B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Merck & Co., Inc. Shs Unsponsored Brazilian Depository Receipt Repr 0.125 Sh's stock has gained approximately 57.18% over the past 52 weeks. The 50-day moving average sits at 94.08, while the 200-day moving average is 80.70.

Over the twelve months ended June 30, 2026, Merck & Co., Inc. Shs Unsponsored Brazilian Depository Receipt Repr 0.125 Sh generated 344.10B in revenue and converted that into 16.40B in net income, yielding earnings per share of 0.83. EBITDA reached 67.68B, while operating income came in at 36.11B.

As of June 30, 2026, Merck & Co., Inc. Shs Unsponsored Brazilian Depository Receipt Repr 0.125 Sh holds 36.91B in cash and equivalents against 278.64B in total debt, resulting in a net debt position of 243.24B. Total book value stands at 216.75B, with working capital of 46.25B providing operational flexibility.

Merck & Co., Inc. Shs Unsponsored Brazilian Depository Receipt Repr 0.125 Sh produced 103.21B in operating cash flow over the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Merck & Co., Inc. Shs Unsponsored Brazilian Depository Receipt Repr 0.125 Sh posted a gross margin of 72.97, reflecting its pricing power and cost economics. The operating margin of 10.49 and net profit margin of 4.77 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Merck & Co., Inc. Shs Unsponsored Brazilian Depository Receipt Repr 0.125 Sh paid dividends of 2.17 per share. The dividend payout ratio of 262.18 exceeds 100%, meaning the company is distributing more than it earns and funding the dividend from cash reserves, asset sales, or borrowing, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 6.23, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield is negative at -1.93, meaning Merck & Co., Inc. Shs Unsponsored Brazilian Depository Receipt Repr 0.125 Sh raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Merck & Co., Inc. Shs Unsponsored Brazilian Depository Receipt Repr 0.125 Sh's most recent stock split took place on October 29, 2020 with a 1:8 split ratio.

As of June 30, 2026, Merck & Co., Inc. Shs Unsponsored Brazilian Depository Receipt Repr 0.125 Sh has an Altman Z-Score of 4.45, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.